OLSALAZINE SODIUM

OLSALAZINE SODIUM
(ol-sal'a-zeen)
Dipentum
Classifications: mucous membrane; antiinflammatory agent;
Therapeutic: antiinflammatory
; gi
Prototype: Mesalamine
Pregnancy Category: C

Availability

250 mg capsules

Action

Converted to 5-aminosalicylic acid (5-ASA) by colonic bacteria. The 5-ASA is absorbed slowly, resulting in a very high local concentration in the colon. 5-ASA inhibits prostaglandin production in the colon, thus leading to anti-inflammatory properties of the drug.

Therapeutic Effect

5-ASA has antiinflammatory activity in ulcerative colitis.

Uses

Maintenance therapy in patients with ulcerative colitis.

Unlabeled Uses

Acute flare-up of ulcerative colitis.

Contraindications

Hypersensitivity to salicylates or 5-ASA; pregnancy (category C).

Cautious Use

Patients with preexisting kidney disease; lactation. Safety and effectiveness in children are not established.

Route & Dosage

Ulcerative Colitis
Adult: PO 500 mg b.i.d., may increase up to 1.5–3 g/d in 2–4 divided doses

Administration

Oral
  • Give with food in two evenly divided doses.

Adverse Effects (≥1%)

CNS: Headache. GI: Diarrhea, nausea, abdominal pain, indigestion, vomiting, bloating. Skin: Rash. Body as a Whole: Arthralgia.

Pharmacokinetics

Absorption: 1–3% from GI tract; high colonic concentrations are associated with efficacy. Metabolism: Olsalazine, a prodrug, is composed of 2 molecules of 5-ASA; colonic bacterial azo-reductases break the azo bond, releasing 2 active molecules of 5-ASA. Elimination: Primarily in feces as 5-ASA. Half-Life: At least 6 h.

Nursing Implications

Assessment & Drug Effects

  • Monitor kidney function in patients with preexisting renal disease.
  • Monitor for S&S of a hypersensitivity reaction (see Appendix F). Withhold olsalazine and notify physician at first sign of an allergic response.

Patient & Family Education

  • Report diarrhea, a possible adverse effect, to the physician.

Common adverse effects in italic, life-threatening effects underlined; generic names in bold; classifications in SMALL CAPS; Canadian drug name; Prototype drug

(43)
This site is intended for general information only. The information provided on this site does not constitute medical advice and should not be relied upon. You should not act or refrain from acting on any legal or medical matter based on the content of this site.
© 2006-2025 medpill.info Last Updated On: 03/09/2025 (0)
×
Wait 20 seconds...!!!